Highlights•GLP-1 analogs can cross the blood–brain barrier and stimulate the GLP-1
receptor in the brain.•Stimulation of the GLP-1 receptor has shown effects on mitochondrial …

Aging is a crucial risk factor for common neurodegenerative diseases, such as Alzheimer's
disease (AD) and Parkinson's disease (PD). Limited options are available for the treatment …

Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been
identified as a risk factor for progressive neurodegenerative disorders such as Alzheimer's …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Introduction Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-
1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson's …

There is increasing interest in the potential role of glucagon-like peptide-1 (GLP-1) receptor
agonists as neuroprotective treatments in neurodegenerative diseases including …

Glucagon-like peptide-1 (7-36)-amide (GLP-1) is an insulinotropic hormone, secreted from
the enteroendocrine L cells of the intestinal tract in response to nutrient ingestion. It …

The current absence of effective treatments for Alzheimer's disease (AD) and Parkinson's
disease (PD) reflects an incomplete knowledge of the underlying disease processes …

Glucagon‐like peptide 1 (GLP‐1) is a relatively recently discovered molecule originating in
the so‐called L‐cells of the intestine. The peptide has insulinotrophic properties and it is this …

Molecular communications in the gut–brain axis, between the central nervous system and
the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in …